Table 1

Patient characteristics

Age, yr [median (range)]b60 (20–74)
Gender, male54 (50/93)
    White91 (85/93)
    African-American8 (7/93)
    Middle Eastern1 (1/93)
BMI ≥ 30b24 (22/93)
Body wt ≥ 100 kgb14 (13/93)
Underlying lung diseases
    Chronic obstructive pulmonary disease39 (36/93)
    Idiopathic pulmonary fibrosis27 (25/93)
    Cystic fibrosis13 (12/93)
    Pulmonary fibrosis (nonidiopathic)5 (5/93)
    Sarcoidosis3 (3/93)
    Scleroderma3 (3/93)
    Primary pulmonary hypertension2 (2/93)
    Miscellaneousc8 (7/93)
Underlying liver diseaseb,d3 (3/93)
Type of transplant
    Double lung80 (74/93)
    Single lung19 (18/93)
    Heart-lung1 (1/93)
Route of voriconazole administratione
    Oral74 (69/93)
    Nasogastric tube (suspension)26 (24/93)
  • a All values except for age are the percentages of patients (number of patients/total number of patients) with the characteristic.

  • b At the time of the transplant. BMI, body mass index.

  • c One patient each had eosinophilic granuloma, primary ciliary dyskinesia, pneumoconiosis, lymphangioleiomyomatosis, alpha-1 anti-trypsin deficiency syndrome, congenital heart disease, and another transplant.

  • d All three patients had mild liver disease. One patient had liver disease resulting from cystic fibrosis, one had liver disease resulting from congenital heart disease, right heart failure and liver congestion, and one had liver disease resulting from hepatitis C virus infection and alcohol abuse.

  • e At the time of the initial level.